Response Assessment in Neuro-Oncology

作者: Eudocia C. Quant , Patrick Y. Wen

DOI: 10.1007/S11912-010-0143-Y

关键词:

摘要: Accuracy and reproducibility in determining response to therapy tumor progression can be difficult achieve for nervous system tumors. Current criteria vary depending on the pathology have several limitations. Until recently, most widely used gliomas were “Macdonald criteria,” based two-dimensional measurements neuroimaging studies. However, Response Assessment Neuro-Oncology (RANO) Working Group has published new recommendations high-grade is working other This article reviews current glioma, low-grade brain metastasis, meningioma, schwannoma.

参考文章(48)
Steven A. Rosenberg, Vincent T. DeVita, Samuel Hellman, Cancer : Principles and Practice of Oncology ,(1982)
D R Macdonald, T L Cascino, S C Schold, J G Cairncross, Response criteria for phase II studies of supratentorial malignant glioma. Journal of Clinical Oncology. ,vol. 8, pp. 1277- 1280 ,(1990) , 10.1200/JCO.1990.8.7.1277
Scott R Plotkin, Chris Halpin, Jaishri O Blakeley, William H Slattery, D Bradley Welling, Susan M Chang, Jay S Loeffler, Gordon J Harris, A Gregory Sorensen, Michael J McKenna, Fred G Barker, None, Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma Journal of Neuro-oncology. ,vol. 93, pp. 61- 77 ,(2009) , 10.1007/S11060-009-9867-7
A Gregory Sorensen, Tracy T Batchelor, Patrick Y Wen, Wei-Ting Zhang, Rakesh K Jain, Response criteria for glioma. Nature Reviews Clinical Oncology. ,vol. 5, pp. 634- 644 ,(2008) , 10.1038/NCPONC1204
A. D. Norden, G. S. Young, K. Setayesh, A. Muzikansky, R. Klufas, G. L. Ross, A. S. Ciampa, L. G. Ebbeling, B. Levy, J. Drappatz, S. Kesari, P. Y. Wen, Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. ,vol. 72, pp. 779- 787 ,(2008) , 10.1212/01.WNL.0000304121.57857.38
J. G. Cairncross, D. R. Macdonald, J. H. Warwick Pexman, F. J. Ives, Steroid-induced CT changes in patients with recurrent malignant glioma Neurology. ,vol. 38, pp. 724- 724 ,(1988) , 10.1212/WNL.38.5.724
Raffaele Addeo, Carmine De Rosa, Vincenzo Faiola, Luigi Leo, Gregorio Cennamo, Liliana Montella, Rosario Guarrasi, Bruno Vincenzi, Michele Caraglia, Salvatore Del Prete, Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases Cancer. ,vol. 113, pp. 2524- 2531 ,(2008) , 10.1002/CNCR.23859
Martin M. Henegar, Christopher J. Moran, Daniel L. Silbergeld, Early postoperative magnetic resonance imaging following nonneoplastic cortical resection Journal of Neurosurgery. ,vol. 84, pp. 174- 179 ,(1996) , 10.3171/JNS.1996.84.2.0174
Patrick Y. Wen, Andrew D. Norden, Jan Drappatz, Eudocia Quant, Response Assessment Challenges in Clinical Trials of Gliomas Current Oncology Reports. ,vol. 12, pp. 68- 75 ,(2010) , 10.1007/S11912-009-0078-3
Gabriele Bergers, Douglas Hanahan, Modes of resistance to anti-angiogenic therapy Nature Reviews Cancer. ,vol. 8, pp. 592- 603 ,(2008) , 10.1038/NRC2442